Seoul BalGeunSeSang Eye Clinic,Reviews,Images, Promotions

What we checked1

All doctors named with photos

Answered by the clinic to MISOODA’s 27-point check — 0 of 27 answered. Anything unanswered is left blank, not assumed.

About this clinic

Seoul BalgeunSeSang Eye Clinic is the global leader in refractive surgery. The Clinic is the first generation of those that have introduced Lasik and Lasek surgery to Korea, and offers safe and premium medical service with over 350 thousand and counting refractive surgeries done. With much experience and expertise in refractive surgery, the hospital has gained much acclaim not only in Korea, but also around the world.
The Clinic has been the leader in state of the art refractive surgery since 1997, and in the year 2011, it has received accreditation from world-famous Joint Commission International, the first eye hospital to do so in Korea. JCI organization recognized Seoul BalgeunSeSang Eye Clinic's superb service, and has proven that the hospital can compete with the very best around the world. 150 or less characters

How this is checked

Operating room CCTV: Under the Medical Service Act, Article 38-2, an operating room where general anaesthesia is administered must have CCTV installed. A patient may request to view the recording — the hospital is not required to offer it first.
The surgeon who operates: MISOODA’s 27-point check asks every clinic to state in writing whether the surgeon you consult is the surgeon who operates. Unanswered items are left blank, not assumed.
Who is doing the checking: MISOODA is operated by Medical Korea Service Co., Ltd., registered with the Seoul Metropolitan Government as a Facilitator for International Patients — registration no. A-2014-01-01-1414, valid 23 July 2014 to 25 June 2029. Korean business licence 745-87-00012. Coordinating care in Korea since 2014.
Seoul Medical Tourism Alliance: MISOODA is an affiliated member of the Seoul Medical Tourism Alliance, a programme of the Seoul Metropolitan Government. Certificate of Affiliation held for 2025 to 2027.